Illumina, the leading maker of gene-sequencing machines, is tiny compared with the tech giants of Silicon Valley. But like Google and Facebook, Illumina now finds itself in the cross hairs of antitrust enforcers in the United States and Europe.The company bought Grail, a promising start-up in a related business that does not really exist yet. Grail developed a blood test for the early detection of dozens of kinds of cancer. It is the early leader in this technology, but many other companies are developing products for what one day could be a huge global market for medical technology. All of them rely on Illumina’s gene sequencers.Illumina announced its acquisition plan in September 2020. Six months …
